BC Extra | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of...
BC Extra | Jan 7, 2020
Company News

Management tracks: New director for CMS’s CMMI, plus FibroGen, Turning Point, Akcea, Antengene, Biocon and more

CMS appointed Brad Smith as director of the Center for Medicare & Medicaid Innovation , through which HHS plans to implement the Trump administration’s proposed International Pricing Index model for Medicare Part B drugs. Smith, who...
BC Extra | Nov 15, 2019
Financial News

Despite flurry of deals, follow-ons well short of 2018’s total

Four companies led by Reata raised over $600 million in follow-ons ahead of Thursday’s trading session, but even with the bolus of funding this year’s follow-ons lag last year’s pace. A fifth company, Halozyme Therapeutics...
BC Extra | Nov 4, 2019
Clinical News

Halozyme to focus on Enhanze partnering after Phase III oncology miss

With the failure of Halozyme's lead cancer program in a Phase III trial, the company intends to exit the oncology R&D field entirely and focus on deriving partner revenue from its subcutaneous drug delivery technology...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | Jun 4, 2019
Politics & Policy

BIO appoints Levin chairman

BIO elected as its new chairman Jeremy Levin, who is chairman and CEO of Ovid Therapeutics Inc. (NASDAQ:OVID). He succeeds John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). The Biotechnology Innovation Organization elected Ted Love...
BC Extra | May 6, 2019
Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and remains...
BC Week In Review | Feb 28, 2019
Clinical News

Subcutaneous daratumumab non-inferior to IV formulation in Phase III

Genmab A/S (CSE:GEN; Pink:GMXAY) said subcutaneous daratumumab met the co-primary endpoints of non-inferiority to IV daratumumab in the Phase III COLUMBA (MMY3012) trial to treat relapsed or refractory multiple myeloma. Partner Janssen Biotech Inc. told...
BC Extra | Feb 25, 2019
Clinical News

Subcutaneous daratumumab non-inferior to IV formulation in Phase III

Genmab A/S (CSE:GEN; Pink:GMXAY) said subcutaneous daratumumab met the co-primary endpoints of non-inferiority to IV daratumumab in the Phase III COLUMBA (MMY3012) trial to treat relapsed or refractory multiple myeloma. Partner Janssen Biotech Inc. told...
BC Week In Review | Feb 8, 2019
Company News

Halozyme grants argenx access to Enhanze subcutaneous delivery tech

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted argenx S.E. (NASDAQ:ARGX) exclusive rights to use Halozyme's Enhanze subcutaneous drug delivery technology in combination with any product targeting the human neonatal Fc receptor FcRn, including argenx lead compound efgartigimod...
Items per page:
1 - 10 of 384
BC Extra | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of...
BC Extra | Jan 7, 2020
Company News

Management tracks: New director for CMS’s CMMI, plus FibroGen, Turning Point, Akcea, Antengene, Biocon and more

CMS appointed Brad Smith as director of the Center for Medicare & Medicaid Innovation , through which HHS plans to implement the Trump administration’s proposed International Pricing Index model for Medicare Part B drugs. Smith, who...
BC Extra | Nov 15, 2019
Financial News

Despite flurry of deals, follow-ons well short of 2018’s total

Four companies led by Reata raised over $600 million in follow-ons ahead of Thursday’s trading session, but even with the bolus of funding this year’s follow-ons lag last year’s pace. A fifth company, Halozyme Therapeutics...
BC Extra | Nov 4, 2019
Clinical News

Halozyme to focus on Enhanze partnering after Phase III oncology miss

With the failure of Halozyme's lead cancer program in a Phase III trial, the company intends to exit the oncology R&D field entirely and focus on deriving partner revenue from its subcutaneous drug delivery technology...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | Jun 4, 2019
Politics & Policy

BIO appoints Levin chairman

BIO elected as its new chairman Jeremy Levin, who is chairman and CEO of Ovid Therapeutics Inc. (NASDAQ:OVID). He succeeds John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). The Biotechnology Innovation Organization elected Ted Love...
BC Extra | May 6, 2019
Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and remains...
BC Week In Review | Feb 28, 2019
Clinical News

Subcutaneous daratumumab non-inferior to IV formulation in Phase III

Genmab A/S (CSE:GEN; Pink:GMXAY) said subcutaneous daratumumab met the co-primary endpoints of non-inferiority to IV daratumumab in the Phase III COLUMBA (MMY3012) trial to treat relapsed or refractory multiple myeloma. Partner Janssen Biotech Inc. told...
BC Extra | Feb 25, 2019
Clinical News

Subcutaneous daratumumab non-inferior to IV formulation in Phase III

Genmab A/S (CSE:GEN; Pink:GMXAY) said subcutaneous daratumumab met the co-primary endpoints of non-inferiority to IV daratumumab in the Phase III COLUMBA (MMY3012) trial to treat relapsed or refractory multiple myeloma. Partner Janssen Biotech Inc. told...
BC Week In Review | Feb 8, 2019
Company News

Halozyme grants argenx access to Enhanze subcutaneous delivery tech

Halozyme Therapeutics Inc. (NASDAQ:HALO) granted argenx S.E. (NASDAQ:ARGX) exclusive rights to use Halozyme's Enhanze subcutaneous drug delivery technology in combination with any product targeting the human neonatal Fc receptor FcRn, including argenx lead compound efgartigimod...
Items per page:
1 - 10 of 384